CURRICULUM VITAE

ANDREW R. HOFFMAN, M.D.

Building 100, Room D4-132
Department of Veterans Affairs Palo Alto Health Care System
3801 Miranda Avenue
Palo Alto, California 94304

Phone: (650) 858-3930 *FAX* (650) 856-8024 *e-mail*: arhoffman@ stanford.edu

EDUCATION

1967-1971	B.A. (History), University of Michigan
1971-1976	M.D., Stanford University School of Medicine

CLINICAL AND RESEARCH TRAINING

1976-1978	Intern and Resident in Medicine Massachusetts General Hospital; Boston, MA
1978-1980	Research Associate in Pharmacology; Laboratory of Clinical Science National Institute of Mental Health; Bethesda, MD
1980-1982	Clinical and Research Fellow in Medicine (Endocrinology); MGH
1981-1982	Clinical and Research Fellow in Gynecology (Reproductive Endocrinology); MGH
1990-1991	Visiting Scientist (Sabbatical), Genentech, Inc.; South San Francisco, CA

APPOINTMENTS

1982-1988	Assistant Professor of Medicine, Stanford University School of Medicine; Stanford, CA
1985-1986	Acting Chief, Division of Endocrinology
1988-2000	Chief, Medical Service, VA Palo Alto Health Care System (VAPAHCS)
1988-2001	Associate Chair, Department of Medicine, Stanford University School of Medicine
1988-1995	Associate Professor of Medicine (tenure)
1988-2003	Associate Professor and Professor of Molecular & Cellular Physiology (by courtesy)
1995-2001	Chief, Division of Endocrinology, Gerontology and Metabolism, Stanford
1995-Present	Professor of Medicine
2004-Present	Associate Chair for Academic Affairs, Department of Medicine, Stanford

BOARD CERTIFICATION

American Board of Internal Medicine
- Internal Medicine, 1979
- Endocrinology and Metabolism, 1981

HONORS AND AWARDS

Phi Beta Kappa (1970)
Alfred P. Sloan Research Fellow (1983-1985)
Mellon Foundation Fellow (1983-1984)
Hume Faculty Scholar (1984-1987)
David A. Rytand Award for Excellence in Clinical Teaching (Medical Housestaff, 1985)
Kaiser Award for Excellence in Clinical Teaching (Medical Students, 1987)
Kaiser Award for Innovative and Outstanding Contributions to Medical Education (Faculty, 1988)
Fisher UCLA Visiting Professor (March 8-10, 2004)

SOCIETIES

American Federation for Clinical Research, 1983
- Medical School Representative, 1988-1989
- Chairman-elect, Western Section, 1989-1990
- Chairman, Western Section, 1990-1991
- Member, National Council 1989-1993
- AFCR Foundation: Trustee 1991-1992; President 1992-1993
- President-elect, 1991-1992
- President, 1992-1993

Endocrine Society, 1983
- Public Communications Committee 1993

Western Society for Clinical Investigation, 1987-2001
- Councilor, 1989-1992
- President-elect, 1993-1994
- President, 1994-1995

Association of VA Chiefs of Medicine, 1988-2000
- Councilor, 1991-1994
- President-elect, 1994
- President, 1995-1997

American College of Physicians (Fellow), 1991-2003
Pituitary Society, 1993
Western Association of Physicians, 1993-2000
- Councilor, 1999-2000

American Society for Clinical Investigation, 1993
Association of American Physicians, 1997

MILITARY SERVICE

United States Public Health Service (Surgeon), 1978-1980

EDITORIAL BOARDS

Hormone and Metabolic Research
- Assistant Editor, 1986-1995
- Co-editor, 1995-present

American Journal of Medicine
- Editorial Board, 1997-1998
- Associate Editor, 1998-present

BioCritique (http://www.biocritique.com)
- Chair, Selection Panel for *Growth Hormone and IGFs*, 2001-present

Journal of Clinical Endocrinology and Metabolism
- Editorial Board, 2004-2008

CLINICAL POSITIONS

1982-Present	Attending Physician, Stanford University Hospital and Palo Alto VAMC
1984-1986	Co-Director, Andrology Clinic; Palo Alto VAMC
1984-1989	Director, Endocrine Clinic; Stanford University Medical Center
1989-2004	Director, Pituitary Clinic; Stanford University Medical Center

TEACHING

1983-Present	Molecular and Cellular Physiology 201: Endocrine Physiology (Course Director, 1985-2002)
1990-1992	Medicine 208: Preparation for Clinical Medicine
1983-Present	Medicine 300: Medicine Clerkship
1982-Present	Medicine 306A: Endocrinology Clerkship
1992-1995	Neurobiology 200

MAJOR COMMITTEE & ADMINISTRATIVE ASSIGNMENTS

Department of Medicine

1985-1988	Quality Assurance Committee, Stanford University Hospital; Chairman, 1987-88
1987-1988	Steering Committee, Stanford University Hospital
1984-1994	Internship Interviewing and Selection Committee
1987-1994	Committee on Residency Training and Clinical Service
1988-1995	Residency Review Committee
1988-2001	Academic Program Chiefs/Leadership Group
1995-1997	Research Committee
2002-Present	Director, Endocrine Training Program
2003-Present	Appointments and Promotions Committee; Chair 2004-Present

Medical School

1985-1988	Admissions Panel
1987-1992	Governing Board, Institute for Biological and Clinical Investigation
1988-1994	Faculty Senate
1989-1990	MSTP Committee
1991-1992	Faculty Budget Advisory Committee
1989-Present	Member, Program in Molecular and Genetic Medicine
1996-1999	Appointments and Promotions Committee Chair (1998-1999)
1998-2000	Task Force on VA and Affiliations
1999	Appointments & Promotions Redesign Project
1997-present	Member, Cancer Biology Program
2004-present	Task Force for LCME Accreditation Site Visit

2004-present Subcommittee on Educational Objectives and Structure, for LCME Visit

Stanford University

1995-7; 2003-4 Faculty Senate
1996-1997 Member, Committee on Committees of the Faculty Senate

VA Medical Center

1988-1991 Clinical Executive Board
1991-2000 Medical Executive Board
1992-1994 Quality Assurance Board
1995-2000 Acting Chief, Geriatrics Research, Education and Clinical Center (GRECC)
1996 Research Committee, VISN 21
1997-2000 Executive Council
2000-2001 Research and Development Committee
2001 Committee on Patient Rights and Organizational Ethics
2000-2001 Acting Associate Chief of Staff for Research and Development
2002-Present Biomedical Research Subcommittee of the R&D Committee
2002-Present Professional Standards Board
2002-Present Chief, Endocrinology Section

National

1992-1995 Research Committee, Association of Professors of Medicine
1999-2003 Medical Research Advisory Group (Endocrinology) (VA)
Chairman, 2001-2003
2000 Scientific Advisory Committee, Genetic Tissue Bank, VA Cooperative Studies Program
2002 VA Biorepository Planning Committee

CONGRESSIONAL TESTIMONY

1992 Feb 27 Testimony on: FY 1993 funding proposals for the Dept. of Veterans Affairs Medical and Health Research Programs. Before: *The Senate Committee on Veterans' Affairs*. Washington DC.

DATA & SAFETY MONITORING BOARDS

Corcept, Inc. (2003-present)
H3 Pharma, Inc (Chair; 2004)

SCIENTIFIC ADVISORY BOARDS

Neurex, Inc. (1988-1991)
Layton Bioscience, Inc. (1992-1995)
Genentech Adult Growth Hormone Advisory Board (1999-present)
GMR Epigenetics (Chairman; 2000-present).

CURRENT FEDERAL GRANT SUPPORT:

NIH R01	DK036054	PI	Mechanisms of Genomic Imprinting 04/01/04-3/31/08
NIH R21	DK065283	PI	Novel Androgen Receptor Associated Non-coding RNA's 07/15//03-7/01/05
NIH U01	AR45583	co-PI	Osteoporosis in Men (MrOs) (Marcia Stefanick, PI) 09/01/01-06/30/06
NIH R01	HL70841	co-PI	Outcomes of Sleep Disorders in Older Men (Marcia Stefanick, PI) 9/01/03-6/30/07
NIH RO1	HD047013	co-PI	The Role of *IGF2* in Fetal Growth Restriction (Pinchas Cohen, PI at UCLA) 06/01/04-05/30/09
VA Merit Review		PI	Role of Insulin-like Growth Factors in Neoplasia 10/01/95-3/31/05
VA Cooperative Study		Local PI	Iron in Atherosclerosis Study (FeAST)
VA Cooperative Study		Local PI	Selenium and Vitamin E Cancer Prevention Trial (SELECT)
Department of Defense		PI	Do capacitively coupled electric fields accelerate tibial stress fracture healing? 09/15/98-11/14//05

CURRENT FOUNDATION SUPPORT

March of Dimes	PI	Epigenetic Complications of In Vitro Fertilization 07/01/04-06/30/07

CURRENT PHARMACEUTICAL SUPPORT

Genentech/Pharmacia/Takeda	PI	Effects of rhGH and pioglitazone in viscerally obese adults with impaired glucose tolerance (Investigator-initiated grant)

BIBLIOGRAPHY

I. JOURNAL ARTICLES

1. Hoffman AR, Ciaranello RD, and Axelrod J. Substrate and inhibitor kinetics of bovine phenylethanolamine N-methyl transferase. Biochem Pharmacol 24: 544-546, 1975.

2. Hoffman AR, Harbaugh R, Erdelyi E, Dornbusch J, Ciaranello R, and Barchas J. Delayed increase in adrenal TH and PNMT activities following cold stress in the mouse. Life Sci 7: 557-562, 1975.

3. Johnson RH, Krupp JR, Hoffman AR, Koplan JP, Nakano JH, and Merigan TC. Nosocomial vaccinia infection. Western J Med 125: 266-270, 1976.

4. Hoffman AR, Paul SM and Axelrod J. Catecholestrogen synthesis and metabolism by human breast tumors in vitro. Cancer Res 39: 4584-4587, 1979.

5. Hoffman AR, Sastry BVR, and Axelrod J. Formation of alpha-methyldopamine ('catecholamphetamine') from p-hydroxyamphetamine by rat brain microsomes. Pharmacology 19: 256-260, 1979.

6. Hoffman AR, Paul SM, and Axelrod J. Estrogen-2-hydroxylase in the rat. Distribution and response to hormonal manipulation. Biochem Pharmacol 29: 83-87, 1980.

7. Hoffman AR, Paul SM, and Axelrod J. The enzymatic formation of catecholestrogens from 2-methoxyestrogens by rat liver microsomes. Endocrinology 107: 1192-1197, 1980.

8. Kloog Y, Flynn D, Hoffman AR, and Axelrod J. Enzymatic carboxymethylation of the nicotinic acetylcholine receptor. Biochem Biophys Res Commun 97: 1474-1480, 1980.

9. Gagnon C, Kelly S, Manganiello V, Vaughan M, Odya C, Strittmatter WJ, Hoffman A, and Hirata F. Modification of calmodulin function by enzymatic carboxyl methylation. Nature 291: 516-517, 1981.

10. Hoffman AR, Majchrowicz E, Poth MA, and Paul SM. Ethanol reduces hepatic estrogen-2-hydroxylase activity in the male rat. Life Sci 29: 789-794, 1981.

11. Hoffman AR and Crowley WF, Jr. Induction of puberty in men by long-term pulsatile administration of low dose gonadotropin-releasing hormone. N Engl J Med 307: 1237-1241, 1982.

12. Reisine T and Hoffman AR. Desensitization of corticotropin-releasing factor receptors. Biochem Biophys Res Commun 111: 552-557, 1983.

13. Seidenwurm D, Elmer EB, Kaplan LM, Williams EK, Morris DG, and Hoffman AR. Metastases to the adrenal glands and the development of Addison's disease. Cancer 54: 552-557, 1984.

14. Rosenfeld RG, Ceda G, Wilson DM, Dollar LA, and Hoffman AR. Characterization of high affinity receptors for insulin-like growth factors I and II on rat anterior pituitary cells. Endocrinology 114: 1571-1575, 1984.

15. Wilson DM, Ceda GP, Bostwick DG, Webber RJ, Minkoff JR, Pont A, Hintz RL, Bensch KG,

Kraemer FB, Rosenfeld RG and Hoffman AR. Acromegaly and Zollinger-Ellison syndrome secondary to an islet cell tumor: Characterization and quantification of plasma and tumor human growth hormone releasing factor. J Clin Endocrinol Metab 59: 1002-1005, 1984.

16. Bostwick DG, Quan R, Hoffman AR, Webber RJ, Chang K, and Bensch KG. Growth hormone releasing factor immunoreactivity in human endocrine tumors. Am J Pathol 117: 167-170, 1984.

17. Hoffman AR, Ceda G, and Reisine TD. Corticotropin releasing factor desensitization of adrenocorticotropic hormone release is augmented by arginine vasopressin. J Neurosci 5: 234-242, 1985.

18. Seidenwurm D, Smathers RL, Kan P, and Hoffman AR. Ultrasound diagnosis of intratesticular adrenal rests. Radiology 155: 479-481, 1985.

19. Ceda GP and Hoffman AR. Growth hormone-releasing factor desensitization in rat anterior pituitary cells in vitro. Endocrinology 116: 1334-1340, 1985.

20. Ceda GP, Hoffman AR, Silverberg GD, Wilson DM, and Rosenfeld RG. Regulation of growth hormone release from cultured human pituitary adenomas by somatomedins and insulin. J Clin Endocrinol Metab 60: 1204-1209, 1985.

21. Dunaif A, Hoffman AR, Scully RE, Flier JS, Longcope C, Levy LJ, and Crowley WF, Jr. The clinical, biochemical and ovarian morphological features in women with acanthosis nigricans and masculinization. Obstet Gynecol 66: 545-552, 1985.

22. Spratt DI, Crowley WF, Jr, Butler JP, Hoffman AR, Conn PM and Badger TM. Pituitary luteinizing hormone responses to intravenous and subcutaneous administration of gonadotropin-releasing hormone in men. J Clin Endocrinol Metab 61: 890-895, 1985.

23. Rosenfeld RG, Ceda G, Cutler CW, Dollar LA and Hoffman AR. Insulin and insulin-like growth factor (somatomedin) receptors on cloned rat pituitary tumor cells. Endocrinology 117: 2008-2016, 1985.

24. Ceda GP and Hoffman AR. Glucocorticoid modulation of corticotropin releasing factor desensitization in cultured rat anterior pituitary cells. Endocrinology 118: 58-62, 1986.

25. Kapsner P, Langsdorf L, Marcus R, Kraemer FB, and Hoffman AR. Milk-alkali syndrome in patients treated with calcium carbonate after cardiac transplantation. Arch Intern Med 146: 1965-1968, 1986.

26. Ceda GP, Valenti G, Butturini U, and Hoffman AR. Diminished pituitary responsiveness to growth hormone releasing factor in aging male rats. Endocrinology 118: 2109-2114, 1986.

27. Wilson DM and Hoffman AR. Reduction of pituitary size by the somatostatin analog SMS 201-995 in a patient with an islet cell tumor secreting growth hormone releasing factor. Acta Endocrinol 113: 23-28, 1986.

28. Roth KA, Wilson DM, Eberwine J, Dorin RI, Kovacs K, Bensch KG, and Hoffman AR. Acromegaly and pheochromocytoma: A multiple endocrine syndrome caused by a plurihormonal

adrenal medullary tumor. J Clin Endocrinol Metab 63: 1421-1426, 1986.

29. Ceda GP, Davis RG, and Hoffman AR. Glucocorticoid modulation of growth hormone (GH) secretion in vitro: Evidence for a biphasic effect on GH-releasing factor mediated release. Acta Endocrinol 114: 465-469, 1987.

30. Seidenwurm D, Smathers RL, Lo RK, Carrol CL, Bassett J and Hoffman AR. Testes and scrotum: MR imaging at 1.5 T. Radiology 164: 393-398, 1987.

31. Roth KA, Bensch KG and Hoffman AR. Characterization of opioid peptides in human thyroid medullary carcinoma. Cancer 59: 1594-1598, 1987.

32. Ceda GP, Davis RG, Rosenfeld RG, and Hoffman AR. The growth hormone (GH) releasing hormone (GHRH)-GH-somatomedin axis: Evidence for rapid inhibition of GHRH-elicited GH release by insulin-like growth factors I and II. Endocrinology 120: 1658-1662, 1987.

33. Kalinyak JE, Dorin RI, Hoffman AR, and Perlman AJ. Tissue specific regulation of glucocorticoid receptor mRNA by dexamethasone. J Biol Chem 262: 10441-10444, 1987.

34. Harjula A, Baldwin JC, Hoffman AR, Billingham ME, and Shumway NE. Comparative effect of cyclosporin A and G on weight gain of primates during the pubertal growth period. J Heart Transplant 6: 222-227, 1987.

35. Roth KA, Newell DC, Dorin RI, Eberwine JE, and Hoffman AR. Aberrant production and regulation of proopiomelanocortin-derived peptides in ectopic Cushing's syndrome. Horm Metabol Res 20: 225-229, 1988.

36. Wilson DM, Perkins SN, Thomas JA, Seelig S, Berry SA, Hamm TE Jr, Hoffman AR, Hintz RL, and Rosenfeld RG. Effects of elevated serum insulinlike growth factor-II on growth hormone and insulinlike growth factor-I mRNA and secretion. Metabolism 38: 57-62, 1989.

37. Ocrant I, Valentino KL, Hoffman AR, Hintz RL, Wilson DM, and Rosenfeld RG. Structural characterization and immunohistochemical localization of receptors for insulin-like growth factor-II in the rat pituitary gland. Neuroendocrinology 49: 248-254, 1989.

38. Geary ES, Rosenfeld RG, and Hoffman AR. Insulin-like growth factor-I is internalized after binding to the type I insulin-like growth factor receptor. Horm Metabol Res 21: 1-3, 1989.

39. Ceda GP, Denti L, Ceresini G, Rastelli G, Dotti C, Cavalieri S, Valenti G, and Hoffman AR. Calcitonin inhibition of growth hormone-releasing hormone-induced GH secretion in normal men. Acta Endocrinol 120: 416-422, 1989.

40. Geary ES, Lim M, Ceda GP, Ro S, Rosenfeld RG, and Hoffman AR. Triiodothyronine regulates insulin-like growth factor-I binding to cultured rat pituitary cells . J Neuroendocrinol 1: 179-184, 1989.

41. Ceda GP, Ceresini G, Denti L, Cortellini P, Hoffman AR, and Valenti G. Androgens do not regulate the growth hormone response to GHRH in elderly men. Horm Metabol Res 21: 695-696, 1989.

42. Kalinyak JE, Griffin CA, Hamilton RW, Bradshaw JG, Perlman AJ, and Hoffman AR. Developmental and hormonal regulation of glucocorticoid receptor mRNA in the rat. J Clin Invest 84: 1843-1848, 1989.

43. Ceda GP, Denti L, Ceresini G, Cortellini P, Banchini A, Frattini A, Hoffman AR, and Valenti G. Secretion of alpha-subunit and intact gonadotropins after surgical and chemical castration. Horm Metabol Res 22: 181-184, 1990.

44. Tavangar K, Hoffman AR, and Kraemer FB. A micromethod for the isolation of total RNA from adipose tissue. Anal Biochem 186: 60-63, 1990.

45. Swislocki ALM, Camargo CA and Hoffman AR. McCune-Albright syndrome: a case of primary hypogonadism obscured by hyperprolactinemic hypogonadotropic hypogonadism. West J Med 153: 653-656, 1990

46. Peabody CA, Warner MD, Markoff E, Hoffman AR, Wilson DM, and Csernansky JG. Growth hormone response to growth hormone releasing hormone in depression and schizophrenia Psychiatry Research: 33: 269-276, 1990.

47. Ceda GP, Ceresini G, Denti L, Magnani D, Marchini L, Valenti G, and Hoffman AR. Effects of cytidine 5'-diphosphocholine administration on basal and growth hormone-releasing hormone-induced growth hormone secretion in elderly subjects. Acta Endocrinol 124: 516-520, 1991.

48. Ceda GP, Denti L, Ceresini G, Hoffman AR, and Valenti G. The effects of aging on the secretion of the common alpha-subunit of the glycoprotein hormones in men. J Amer Geriatr Soc 39: 353-358, 1991.

49. Ceda GP, Fielder PJ, Henzel WJ, Louie A, Donovan SM, Hoffman AR, and Rosenfeld RG. Differential effects of insulin-like growth factor (IGF)-I and IGF-II on the expression of IGF binding proteins (IGFBPs) in a rat neuroblastoma cell line: isolation and characterization of two forms of IGFBP-4. Endocrinology 128: 2815-2824, 1991.

50. Kalinyak JE, Hoffman AR, and Perlman AJ. Ontogeny of angiotensinogen mRNA and angiotensin II receptors in brain and liver. J Endocrinol Invest 14: 647-653, 1991.

51. Kraemer FB, Tavangar K, and Hoffman AR. Developmental regulation of hormone sensitive lipase mRNA in the rat: changes in steroidogenic tissues. J Lipid Res 32:1303-1310, 1991.

52. Tavangar K, Murata Y, Patel S, Kalinyak JE, Pedersen ME, Goers JF, Hoffman AR, and Kraemer FB. Developmental regulation of lipoprotein lipase in the rat. Am J Physiol 262 (Endocrinol Metab 25): E330-E337, 1992.

53. Ceda GP, Fielder PJ, Donovan SM, Rosenfeld RG, and Hoffman AR. Regulation of insulin-like growth factor-binding protein expression by thyroid hormone in rat GH3 pituitary tumor cells. Endocrinology 130: 1483-1489, 1992.

54. Lieberman SA, Bukar J, Chen SA, Celniker AC, Compton PG, Cook J, Albu J, Perlman AJ, and Hoffman AR. Effects of recombinant human insulin-like growth factor-I (rhIGF-I) on total and free IGF-I concentrations, IGF binding proteins, and glycemic response in humans. J Clin Endocrinol Metab 75: 30-36, 1992.

55. Tavangar K, Murita Y, Pedersen ME, Goers JF, Hoffman AR and Kraemer FB. Regulation of lipoprotein lipase in the diabetic rat. J Clin Invest 90:1672-1678, 1992.

56. Eberwine JH, Newell D, Spencer C, and Hoffman AR. Messenger RNA structure, in situ, as assessed by microscopic techniques. Microsc Res Technique 25: 19-28, 1993.

57. Nanto-Salonen K, Muller HL, Hoffman AR, Vu TH, and Rosenfeld RG. Mechanisms of thyroid hormone action on the insulin-like growth factor system: all thyroid hormone effects are not growth hormone mediated. Endocrinology 132: 781-788, 1993.

58. Giudice LC, Dsupin BA, Vu T, Jin IH, and Hoffman AR. Differential expression of messenger ribonucleic acids encoding insulin-like growth factors and their receptors in human uterine endometrium and decidua. J Clin Endocrinol Metab 76: 1115-1122, 1993.

59. Giudice LC, Irwin JC, Dsupin BA, Pannier EM, Jin IH, Vu TH, and Hoffman AR. Insulin-like growth factor (IGF), IGF binding protein (IGFBP) and IGF receptor gene expression and IGFBP synthesis in human uterine leiomyomata. Hum Reprod 11: 1796-1803, 1993.

60. Fujishima S, Hoffman AR, Vu T, Kim KJ, Zheng H, Daniel D, Kim Y, Wallace EF, Larrick JW, Raffin TA. Regulation of neutrophil interleukin 8 gene expression and protein secretion by LPS, TNF-α, and IL-1ß. J Cell Physiol 154: 478-485, 1993.

61. Kalinyak JE, Sechi LA, Griffin CA, Don BR, Tavangar K, Kraemer FB, Hoffman AR and Schambelan M. The renin-angiotensin system in streptozotocin-induced diabetes in the rat. J Am Soc Nephrol 4: 1337-1345, 1993.

62. Dell'Aglio E, Valenti G, Hoffman AR, Zuccarelli A, Passari G, and Ceda GP. Lack of effect of transdermal estrogen on the growth hormone-insulin-like growth factor axis. Horm Metabol Res 26: 211-212, 1994.

63. Lieberman SA, Butterfield GE, Harrison D and Hoffman AR. Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 78: 404-410, 1994.

64. Lieberman SA, Mitchell AM, Hintz R, Marcus R, and Hoffman AR. The insulin-like growth factor-I generation test: resistance to growth hormone during aging and estrogen replacement therapy Horm Metabol Res 26: 229-233, 1994.

65. Lieberman SA, Holloway L, Marcus R, and Hoffman AR. Interactions of growth hormone and parathyroid hormone in renal phosphate, calcium and calcitriol metabolism and bone remodeling in postmenopausal women. J Bone Miner Res 9: 1723-1728, 1994.

66. Taaffe DR, Pruit L, Reim J, Hintz RL, Butterfield G, Hoffman AR, and Marcus R. Effect of recombinant human growth hormone on the muscle strength response to resistance exercise in elderly men. J Clin Endocrinol Metab 79: 1361-1366, 1994.

67. Vu TH and Hoffman AR. Promoter-specific imprinting of the human insulin-like growth factor-II gene. Nature 371: 714-717, 1994.

68. Vu TH, Yballe C, Boonyanit S, and Hoffman AR. Insulin-like growth factor-II in uterine

smooth muscle tumors: maintenance of genomic imprinting in leiomyomata and loss of imprinting in leiomyosarcomata. J Clin Endocrinol Metab 80: 1670-1676, 1995.

69. Tsao T, Wang J, Fervenza F, Vu TH, Jin IH, Hoffman AR, and Rabkin R. Renal growth hormone-insulin-like growth factor-I system in acute renal failure. Kidney Int 47: 1658-1668, 1995.

70. Thompson JL, Butterfield GE, Marcus R, Hintz RL, Van Loan M, Ghiron L, and Hoffman AR. The effects of recombinant human insulin-like growth factor-I and growth hormone on body composition in elderly women. J Clin Endocrinol Metab 80: 1845-1852, 1995.

71. Hu JF, Vu TH, and Hoffman AR. Differential biallelic activation of three insulin-like growth factor-II promoters in the mouse central nervous system. Mol Endocrinol 9: 628-636, 1995.

72. Ghiron LJ, Thompson JL, Holloway L, Hintz RL, Butterfield GE, Hoffman AR, and Marcus R. Effects of recombinant insulin-like growth factor-I and growth hormone on bone turnover in elderly women. J Bone Miner Res 10: 1844-1852, 1995.

73. Jin IH, Sinha G, Yballe C, Vu TH, and Hoffman AR. The human insulin-like growth factor-II promoter P1 is not restricted to liver: evidence for expression of P1 in other tissues and for a homologous promoter in baboon liver. Horm Metabol Res 27: 447-449, 1995.

74. Taaffe DR, Jin IH, Vu TH, Hoffman AR, and Marcus R. Lack of effect of recombinant human growth hormone (GH) on muscle morphology and GH-insulin-like growth factor expression in resistance-trained elderly men. J Clin Endocrinol Metab 81: 421-425, 1996.

75. Rabkin R, Fervenza FC, Maidment H, Ike J, Hintz R, Liu F, Bloedow DC, Hoffman AR and Gesundheit N. Pharmacokinetics of insulin-like growth factor-I in advanced chronic renal failure. Kidney Int 49: 1134-1140, 1996.

76. Yballe CM, Vu TH and Hoffman AR. The imprinting and expression of insulin-like growth factor-II and *H19* in normal breast tissue and breast tumor. J Clin Endocrinol Metabol 81: 1607-1612, 1996.

77. Vu TH and Hoffman AR. Alterations in the promoter-specific imprinting of the insulin-like growth factor-II gene in Wilms' tumor. J Biol Chem 271: 9014-9023, 1996.

78. Hu JF, Vu TH and Hoffman AR. Promoter-specific modulation of insulin-like growth factor-II genomic imprinting by inhibitors of DNA methylation. J Biol Chem 271: 18253-18262, 1996.

79. Wang WH, Duan JX, Vu TH, and Hoffman AR. Increased expression of the insulin-like growth factor-II gene in Wilms' tumor is not dependent on loss of genomic imprinting or loss of heterozygosity. J Biol Chem 271: 27863-27870, 1996.

80. Tsuchiya K, Maloney WJ, Vu T, Hoffman AR, Schurman DJ and Smith RL. RT-PCR analysis of MMP-9 expression in human articular-cartilage chondrocytes and synovial-fluid cells. Biotech Histochem 71: 208-213, 1996.

81. Butterfield GE, Thompson J, Rennie MJ, Marcus R, Hintz RL, and Hoffman AR. Effect of

rhGH and rhIGF-I treatment on protein utilization in elderly women Am J Physiol 272 (Endocrinol Metab 35): E94-E99, 1997.

82. Fervenza FC, Tsao T, Hoffman AR, and Rabkin R. Regional changes in the intrarenal insulin-like growth factor-I axis in diabetes. Kidney Int 51: 811-818, 1997.

83. Ike JO, Fervenza FC, Hoffman AR, Yeh I, Hintz RL, Liu F, and Rabkin R. Early experience with extended use of insulin-like growth factor-I in advanced chronic renal failure. Kidney Int 51: 840-849, 1997.

84. Dong G, Rajah R, Vu T, Hoffman AR, Rosenfeld RG, Roberts Jr CT, Peehl DM, and Cohen P. Decreased expression of the Wilms' tumor gene WT-1 and elevated expression of insulin-like growth factor-II (IGF-II) and Type 1 IGF receptor genes in prostatic stromal cells from patients with benign prostatic hyperplasia. J Clin Endocrinol Metab 82: 2198-2203, 1997.

85. Tsuchiya K, Maloney WJ, Vu T, Hoffman AR, Huie P, Sibley R, Schurman DJ and Smith RL. Osteoarthritis: differential expression of matrix metalloproteinase-9 mRNA in nonfibrillated and fibrillated cartilage. J Orthopaed Res 15: 94-100, 1997.

86. Hu JF, Vu TH, and Hoffman AR. Genomic deletion of an imprint maintenance element abolishes imprinting of both insulin-like growth factor II and *H19*. J Biol Chem 272: 20715-20720, 1997.

87. Vu TH and Hoffman AR. Imprinting of the Angelman syndrome gene, UBE3A, is restricted to brain. Nature Genet 17: 12-13, 1997.

88. Hu JF, Cheng Z, Chisari FV, Vu TH, Hoffman AR, and TC Campbell. Repression of hepatitis B virus (HBV) transgene and HBV-induced liver injury by a low protein diet. Oncogene 15: 2795-2801, 1997.

89. Hu JF, Nguyen PH, Pham NV, Vu TH, and Hoffman AR. Modulation of *Igf2* genomic imprinting in mice induced by 5-azacytidine, an inhibitor of DNA methylation. Mol Endocrinol 11: 1891-1898, 1997.

90. Ceda GP, Dall'Aglio E, Magnacavallo A, Vargas N, Fontana V, Maggio M, Valenti G, Lee PDK, Hintz RL, and Hoffman AR. The insulin-like growth factor axis and plasma lipid levels in the elderly. J Clin Endocrinol Metab 83: 499-502, 1998.

91. Hu JF, Oruganti H, Vu TH and Hoffman AR. Tissue-specific imprinting of the mouse insulin-like growth factor II receptor gene correlates with differential allele-specific DNA methylation. Mol Endocrinol 12: 220-232, 1998.

92. Thompson JL, Butterfield GE, Gylfadottir UK, Yesavage J, Marcus R, Hintz RL, Pearman A, and Hoffman AR. Effects of human growth hormone, insulin-like growth factor I, and diet and exercise on body composition of obese postmenopausal women. J Clin Endocrinol Metab 83: 1477-1484, 1998.

93. Ulaner GA, Hu JF, Vu TH, Giudice LC, and Hoffman AR. Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and

by alternate splicing of hTERT transcripts. Cancer Res 58: 4168-4172, 1998.

94. Pham NV, Nguyen MT, Hu JF, Vu TH, and Hoffman AR. Dissociation of *IGF2* and *H19* imprinting in human brain. Brain Res 810: 1-8, 1998.

95. Hu JF, Oruganti H, Vu TH, and Hoffman AR. The role of histone acetylation in the allelic expression of the imprinted human insulin-like growth factor II gene. Biochem Biophys Res Commun 251: 403-408, 1998.

96. Hu JF, Balaguru KA, Ivaturi RD, Oruganti H Li T, Vu TH, and Hoffman AR. Lack of reciprocal genomic imprinting of endogenous sense and antisense RNA of mouse insulin-like growth factor II receptor in the central nervous. Biochem Biophys Res Commun 257: 604-608, 1999.

97. Ulaner GA, Hu JF, Vu TH, Oruganti H, Giudice LC, and Hoffman AR. Regulation of telomerase by alternate splicing of human telomerase reverse transcriptase (hTERT) in normal and neoplastic ovary, endometrium, and myometrium. Int J Cancer 85: 330-335, 2000.

98. Vu TH, Li T, Nguyen D, Nguyen BT, Yao XM, Hu JF and Hoffman AR. Symmetric and asymmetric DNA methylation in the human *IGF2-H19* imprinted region. Genomics 64: 132-143, 2000.

99. Hu JF, Ulaner GA, Oruganti H, Ivaturi RD, Balaguru KA, Pham J, Vu TH and Hoffman AR. Allelic expression of the putative tumor suppressor gene p73 in human fetal tissues and tumor specimens. Biochim Biophys Acta 1491: 49-56, 2000.

100. Smith RL, Lin J, Trindade MC, Shida J, Kajiyama G, Vu T, Hoffman AR, van der Meulen MC, Goodman SB, Schurman DJ, and Carter DR. Time-dependent effects of intermittent hydrostatic pressure on articular chondrocyte type II collagen and aggrecan mRNA expression. J. Rehabil Res Dev. 37: 153-161, 2000.

101. Li T, Vu TH, Zeng ZL, Nguyen BT, Hayward BE, Bonthron DT, Hu JF and. Hoffman AR. Tissue-specific expression of antisense and sense transcripts at the imprinted *Gnas* locus. Genomics 69: 295-304, 2000.

102. Hu JF, Pham J, Dey I, Li T, Vu TH, and Hoffman AR. Allele-specific histone acetylation accompanies genomic imprinting of the insulin-like growth factor II receptor gene. Endocrinology 141: 4428-4435, 2000.

103. Okamura K., Hagiwara-Takeuchi Y, Li T, Vu TH, Hirai M, Hattori M, Sakaki Y, Hoffman AR and Ito T. Comparative genome analysis of the mouse imprinted gene *Impact* and its nonimprinted human homolog *IMPACT*: Toward the structural basis for species-specific imprinting. Genome Res 10: 1878-1889, 2000.

104. Ulaner GA Hu JF, Vu TH, Giudice LC, and Hoffman AR. Tissue-specific alternate splicing of human telomerase reverse transcriptase (hTERT) influences telomere lengths during human development. Int J Cancer 91: 644-649, 2001.

105. Taaffe DR, Thompson JL, Butterfield GE, Hoffman AR, and Marcus R. Recombinant human growth hormone, but not insulin-like growth factor-I, enhances central fat loss in postmenopausal women undergoing a diet and exercise program Horm Metab Res 33: 156-62,

2001

106. Friedlander AL, Butterfield GE, Moynihan S, Grillo J, Pollack M, Holloway L, Friedman L, Yesavage J, Matthias D, Lee S, Marcus R, and Hoffman AR. One year of insulin-like growth factor I treatment does not affect bone mineral density, body composition or psychological measures in postmenopausal women. J Clin Endocrinol Metab 86: 1496-1503, 2001.

107. Chu JW, Matthias DF, Belanoff J, Schatzberg A, Hoffman AR, and Feldman D. Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). J Clin Endocrinol Metab 86: 3568-3573, 2001.

108. Killian JK, Nolan CM, Wylie AA, Vu TH, Li T, Hoffman AR, and Jirtle RL. Divergent evolution in *M6P/IGF2R* imprinting from the Jurassic to the Quaternary. Hum Mol Genet 10: 1721-1728, 2001.

109. Li T, Vu TH, Lee KO, Yang Y, Nguyen CV, Bui HQ, Zeng ZL, Nguyen BT, Hu JF, Murphy SK, Jirtle RL, and Hoffman AR. An imprinted PEG1/MEST antisense expressed predominantly in human testis and in mature spermatozoa. J Biol Chem 277: 13518-13527, 2002.

110. Cook DM, Biller BMK, Vance ML, Hoffman AR, Phillips LS, Ford KM, Benzinger DP, Illeperuma A, Blethen SL, Attie KM, Dao LN, Reimann JD and Fielder PJ. The pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (Nutropin Depot) in GH-deficient adults. J Clin Endocrinol Metab 87: 4508-4514, 2002.

111. Yao X, Hu JF, Daniels M, Shiran H, Zhou X, Yan H, Lu H, Zeng Z, Wang Q, Li T, and Hoffman AR. A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma. J Clin Invest 111: 265-273, 2003.

112. Ulaner GA, Vu TH, Li T, Hu JF, Yao XM, Yang Y, Gorlick R, Meyers P, Healey J, Landanyi M, and Hoffman AR. Loss of imprinting of *IGF2* and *H19* in osteosarcoma is accompanied by reciprocal changes in methylation of a CTCF-binding site. Hum Mol Genet 12:535-549, 2003.

113. Ulaner GA, Huang HY, Otero J, Zhao Z, Ben-Porat L, Satagopan JM, Gorlick R, Meyers P, Healey JH, Huvos AG, Hoffman AR, and Ladanyi M. Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Res 63:1759-1763, 2003.

114. Vu TH, Chuyen NV, Li T and Hoffman AR. Loss of imprinting of IGF2 sense and antisense transcripts in Wilms' tumor. Cancer Res 63:1900-1905, 2003.

115. Yao X, Hu JF, Daniels M, Yien H, Lu H, Sharan H, Zhou X, Zeng Z, Li T, Yang Y and Hoffman AR. A novel orthotopic tumor model to study growth factors and oncogenes in hepatocarcinogenesis. Clin Cancer Res 9:2719-2726, 2003.

116. Braun B, Friedlander AL, Pollack M, Butterfield GE, Marcus R, and Hoffman AR. Five weeks of insulin-like growth factor-I treatment does not alter glucose kinetics or insulin sensitivity during a hyperglycemic clamp in older women. Metabolism 52: 1182-1190, 2003.

117. Daniels MW, Wilson DM, Paguntalan HG, Hoffman AR and Bachrach LK. Bone mineral density in pediatric transplant recipients. Transplantation 76:673-678, 2003.

118. Ulaner GA, Yang Y, Hu JF, Li T, Vu TH and Hoffman AR. CTCF binding at the insulin-like growth factor-II (*IGF2)/H19* imprinting control region is insufficient to regulate *IGF2/H19* expression in human tissues. Endocrinology 144: 4420-4426, 2003.

119. Yang Y, Hu JF, Ulaner GA, Li T, Yao X, Vu TH, and Hoffman AR. Epigenetic regulation of *Igf2/H19* imprinting at CTCF insulator binding sites. J Cell Biochem 90:1038-1055, 2003.

120. Yang Y, Li T, Vu TH, Ulaner GA, Hu JF and Hoffman AR. The histone code regulating expression of the imprinted mouse Igf2r gene. Endocrinology 144: 5658–5670, 2003.

121. Meikle AW, Matthias D, and Hoffman AR. Transdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal men. BJU Int 93: 789-795, 2004.

122. Yao X, Hu JF, Li T, Yang Y, Sun Z, Ulaner GA, Vu TH and Hoffman AR. Epigenetic regulation of the taxol resistance-associated gene TRAG-3 in human tumors. Cancer Genet Cytogenet 151: 1-13, 2004.

123. Li T, Vu TH, Ulaner GA, Yang Y, Hu JF and Hoffman AR. Activating and silencing histone modifications form independent allelic switch regions in the imprinted *Gnas* gene. Hum Mol Genet 13: 741-750, 2004.

124. Hoffman AR, Kuntze JE, Baptista J, Baum HBA, Baumann GP, Biller BMK, Clark RV, Cook D, Inzucchi SE, Kleinberg D, Klibanski A, Phillips LS, Ridgway EC, Robbins RJ, Schlechte J, Sharma M, Thorner MO, and Vance ML. Growth hormone (GH) replacement therapy in adult-onset GH deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89: 2048-2056, 2004.

125. Denti L, Annoni V, Cattadori E, Salvagnini MA, Visioli S, Merli MF, Corradi F, Ceresini G, Valenti G, Hoffman AR and Ceda GP. Insulin-like growth factor 1 as a predictor of ischemic stroke outcome in the elderly. Am J Med 117: 312-317, 2004.

126. Hoffman AR, Strasburger CJ, Zagar A, Blum WF, Kehely A and Hartman ML on behalf of the T002 Study Group. Efficacy and tolerability of an individualized dosing regimen for adult growth hormone replacement therapy in comparison with fixed body weight-based dosing. J Clin Endocrinol Metab 89: 3224-3233, 2004.

127. Ulaner GA, Hoffman AR, Otero J, Huang HY, Zhao Z, Mazumdar M, Gorlick R, Meyers P, Healey JH and Ladanyi M. Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas. Genes Chromosomes Cancer 41: 155-162, 2004.

128. Subudhi AW, Jacobs KA, Hagobian TA, Fattor JA, Fulco CS, Muza SR, Rock PB, Hoffman AR, Cymerman A, and Friedlander AL. Antioxidant supplementation does not attenuate oxidative stress at high altitude. Aviat Space Environ Med 75:881-888, 2004.

129. Vu TH, Li T and Hoffman AR. Promoter-restricted histone code, not the differentially methylated DNA regions or antisense transcripts, marks the imprinting status of *IGF2R* in human and mouse. Hum Mol Genet 13: 2233-2245, 2004.

II. CHAPTERS, SYMPOSIA, AND INVITED EDITORIALS AND REVIEWS

1. Paul SM, Hoffman AR, and Axelrod J. Catechol estrogens: Synthesis and metabolism in brain and other endocrine tissues. In : L Martini and WF Ganong (eds.), Frontiers in Neuroendocrinology, Vol 6, Raven Press, New York, pp 203-217, 1980.

2. Gagnon C, Kelly S, Manganiello V, Vaughan M, Strittmatter W, Hoffman A, and Hirata F. Protein carboxyl-methylase modifies calmodulin function. Ann NY Acad Sci 356: 385-386, 1980.

3. Hoffman AR, Poth MA and Axelrod J. Developmental aspects of catecholestrogen synthesis. In: K Fuxe, J-A Gustafsson and L Wetterberg (eds.), Steroid Hormone Regulation of the Brain, Pergamon Press, Oxford, pp 51-59, 1981.

4. Poth MA, Axelrod J, and Hoffman AR. Estrogen-2-hydroxylase: Developmental, hormonal and pharmacologic studies using a radioenzymatic method. In: GR Merriam and MB Lipsett (eds.), Catechol Estrogens, Raven Press, NY, pp 19-30, 1983.

5. Paul SM, Purdy RH, Hoffman AR, and Axelrod J. Radioenzymatic assays for catechol estrogens. In: GR Merriam and MB Lipsett (eds.), Catechol Estrogens, Raven Press, NY, pp 83-90, 1983.

6. Hoffman AR and Crowley WF Jr. Chronic low-dose pulsatile gonadotropin releasing hormone treatment of idiopathic hypogonadotropic hypogonadism in men. In R D'Agata, MB Lipsett, P Polosa and HJ Van der Mohen (eds.), Recent Advances in Male Reproduction: Molecular Basis and Clinical Implications. Raven Press, New York, pp 249-256, 1983.

7. Hoffman AR and Crowley WF Jr. Induction of puberty with chronic administration of low dose pulsatile GnRH. In: G Leyendecker, H Stock, and L Wildt (eds.), Brain and Pituitary Peptides II. Pulsatile Administration of Gn-RH in Hypothalamic Failure: Basic and Clinical Aspects. S. Karger AG, Basel, pp 140-149, 1983.

8. Hoffman AR and Crowley WF Jr. LHRH therapy for hypogonadotropic-hypogonadal men. In: BH Vickery, JJ Nestor Jr, and ESE Hafez (eds.), LHRH and Its Analogs-A New Class of Contraceptive and Therapeutic Agents. MTP Press, Lancaster, pp 285-297, 1984.

9. Hoffman AR and Crowley WF Jr. Chronic administration of low-dose pulsatile GnRH in idiopathic hypogonadotropic hypogonadism. In: JR Givens, (ed.) The Hypothalamus, Year Book Medical Publishers, Inc., Chicago, pp 205-214, 1984.

10. Hoffman AR. Fertility induction in hypothalamic hypogonadism, pp 643-646. In: Cutler GB Jr, moderator. Therapeutic applications of luteinizing-hormone-releasing hormone and its analogs. Ann Intern Med 102: 643-657, 1985.

11. Spratt D, Hoffman AR and Crowley WF Jr. Hypogonadotropic hypogonadism and its treatment. In: RJ Santen and RS Swerdloff (eds.), Male Reproductive Dysfunction. Diagnosis and Management of Hypogonadism, Infertility and Impotence. Marcel Dekker, New York, pp 227-249, 1986.

12. Ceda GP, Narog B, Rosenfeld RG, and Hoffman AR. The role of insulin-like growth factors and

insulin in the regulation of growth hormone secretion. In: GM Molinatti and L Martini (eds.), Endocrinology '85, Elsevier Science Publishers, Amsterdam, pp 147-152, 1986.

13. Ceda GP, Valenti G, Butturini U, and Hoffman AR. Reduced GH pituitary responsiveness to GRF in aged rats. In: P. Vezzadini, A Facchini and G Labo (eds.), Neuroendocrine System and Aging, EURAGE, Rijswijk (The Netherlands), pp 89-95, 1986.

14. Dunaif A and Hoffman AR. Insulin resistance and hyperandrogenism: Clinical syndromes and possible mechanisms. In: P Pancheri, L Zichella (eds.), Biorhythms and Stress in the Physiopathology of Reproduction, Hemisphere Publishing Co, Washington, pp 293-317, 1988.

15. Hoffman AR, Perkins SN, Zangger I, Eberwine J, Barchas JD, James P, Rosenfeld RG, and Hintz RL. Somatomedin gene expression. In: RJ Robbins and S Melmed (eds.), Acromegaly: A Century of Scientific and Clinical Progress, Plenum Press, New York, pp 45-53, 1987.

16. Rosenfeld RG, Ceda GP, Conover CA, Wilson DM, and Hoffman AR. Somatomedin action and tissue growth factor receptors. In: RJ Robbins and S Melmed (eds.), Acromegaly: A Century of Scientific and Clinical Progress, Plenum Press, New York, pp 55-63, 1987.

17. Rosenfeld RG and Hoffman AR. Insulin-like growth factors and their receptors in the pituitary and hypothalamus. In: MK Raizada and D LeRoith (eds.), Insulin, Insulin-like Growth Factors, and Their Receptors in the Central Nervous System, Plenum Press, New York, pp 277-295, 1987.

18. Hoffman AR. Turner syndrome in adult women: two illustrative cases. In: RG Rosenfeld and MM Grumbach (eds.) Turner Syndrome, Marcel Dekker, Inc., New York, pp. 507-510, 1990.

19. Hoffman AR, Griffin C, Kalinyak JE, Perkins SN, and Ceda GP. The hypothalamic-somatotroph-somatomedin axis and aging. In: G Valenti (ed.), Psychoneuroendocrinology of Aging: Basic and Clinical Aspects, Fidia Research Series.Vol. 16, Springer-Verlag, Berlin, pp 43-60, 1988.

20. Rosenfeld RG, Ocrant I, Valentino KL, and Hoffman AR. Interaction of IGF with the hypothalamus and pituitary. In: D LeRoith and MK Raizada (eds). Molecular and Cellular Biology of Insulin-like Growth Factors and Their Receptors. Plenum Press, New York, pp.39-56, 1990.

21. Ceda G, Denti L, Hoffman AR, Ceresini G, and Valenti G. Aging and pituitary responses to hypothalamic peptides. In: HL Segal (ed.), Protein Metabolism in Aging. Wiley- Liss, Inc, New York , pp. 335-344, 1990.

22. Lieberman SA and Hoffman AR. Sequelae to acromegaly: reversibility with treatment of the primary disease. Horm Metabol Res. 22: 313-318, 1990.

23. Hoffman AR and Marcus R. Treatment of Endocrine Disorders: Estrogens and progestins (Chapter 17). In: Melmon KL, Morrelli HF, Hoffman BB, and Nierenberg DW (eds.). Melmon and Morrelli's Clinical Pharmacology: Basic Principles in Therapeutics (3rd edition). McGraw-Hill, Inc., NY., pp. 446-457, 1992.

24. Lieberman SA and Hoffman AR. Treatment of Endocrine Disorders: Hypothalamic hormones (Chapter 18). In: Melmon KL, Morrelli HF, Hoffman BB, and Nierenberg DW (eds.). Melmon and Morrelli's Clinical Pharmacology: Basic Principles in Therapeutics (3rd edition). McGraw-Hill, Inc., NY., pp. 458-468, 1992.

Lieberman SA and Hoffman AR. Hypothalamic hormone therapy. In : Carruthers SG, Hoffman BB, Melmon KL and Nierenberg DW (eds). ibid. (4th edition), pp. 637-644, 2000.

25. Faig JC and Hoffman AR. Endocrine complications. (Chapter XL-16). In: Holland JF, Frei E III, Bast RC, Jr, Kufe DW, Morton DL, and Weichselbaum RR (eds.). Cancer Medicine (3rd edition). Lea & Febiger, Philadelphia, pp. 2398-2402, 1993.

Lieberman SA, Faig JC, and Hoffman AR. Endocrine complications (Chapter 187). ibid. 4th edition. Williams & Wilkins, Baltimore, pp. 3277-3281, 1997.

26. Hoffman AR, Lieberman SA, and Ceda GP. Growth hormone therapy in the elderly: implications for the aging brain. Psychoneuroendocrinology 17: 327-333, 1992.

27. Lieberman SA, Björkengren AG, and Hoffman AR. Rheumatological and skeletal changes in acromegaly. Endocrinol Metabol Clin N Amer 21: 615-631, 1992.

28. Hoffman AR, Pyka G, Lieberman SA, Ceda GP and Marcus R. The Somatopause. In Muller EE, Cocchi D, and Locatelli V (eds). Growth Hormone and Somatomedins During Lifespan. Springer-Verlag. Berlin. pp. 265-274, 1993.

29. Hintz RL, Hoffman AR, Butterfield G, and Marcus RM. The effects and side effects of growth hormone treatment in the adult. In Z. Laron, O. Butenandt, eds. Growth Hormone Replacement Therapy in Adults - Pros and Cons. Freund Publishing House, Tel Aviv. pp 157-170, 1993.

30. Ceda GP, Marzani GP, Tontodonati V, Piovani E, Bachnini A, Baffoni MT, Valenti G, and Hoffman AR. The effects of an acetylcholine precursor on GH secretion in elderly subjects. In: Bercu BB and Walker RR, eds. Growth Hormone II: Basic and Clinical Aspects. Springer-Verlag. New York, pp. 328-337, 1994.

31. Hoffman AR. Book review of: "Ahrens EH Jr. *The Crisis in Clinical Research: Overcoming Institutional Obstacles.* N Engl J Med 328: 1361-1362, 1993.

32. Hoffman AR. Toward a redefinition of the mission of the American Federation for Clinical Research. Clin Res 41: 477-481, 1993.

33. Fielder PJ, Ocrant I, Ceda GP, Hoffman AR, and Rosenfeld RG. Pituitary IGF binding proteins: characterization, expression, and hormonal regulation. In: Melmed S, ed. Molecular and Clinical Advances in Pituitary Disorders-1993. pp. 135-141, 1993.

34. Rosenfeld RG, Hoffman, AR, Adashi EY, Fielder PJ, Ocrant I, and Ceda GP. Effects of insulin-like growth factors on neuroendocrine function. In: Savage MO, Bourguignon J-P, Grossman AB, eds. Frontiers of Paediatric Neuroendocrinology. Blackwell Scientific Publications, Oxford, pp. 156-160, 1994.

35. Hoffman AR, Marcus R, Hintz RL, Butterfield G, Thompson J, Ghiron L, Lieberman S, Dall'Aglio E, and Ceda GP. Effects of recombinant human insulin-like growth factor I in aging. In: Blackman MR, Harman SM, Roth J and Shapiro JR, eds. GHRH, GH and IGF-I: Basic and Clinical Advances . Springer-Verlag, New York, pp. 266-276, 1995.

36. Marcus R. and Hoffman AR. Growth hormone, insulin-like growth factor-I and human aging. In: KT Shiverick and AL Rosenbloom, eds. Human Growth Hormone Pharmacology: Basic and Clinical Aspects. CRC Press, Inc., Boca Raton, FL, pp. 107-120 , 1995.

37. Giudice LC, Irwin JC, Dsupin BA, de las Fuentes L, Jin IH, Vu TH, and Hoffman AR. Insulin-like growth factors (IGFs), IGF binding proteins (IGFBPs), and IGFBP protease in human uterine endometrium: their potential relevance to endometrial cyclic function and maternal-embryonic interactions. In: RC Baxter, PD Gluckman, and RG Rosenfeld, eds. The Insulin-like Growth Factors and Their Regulatory Proteins, pp 351-361, 1994.

38. Lieberman SA and Hoffman AR. Therapeutic implications of the somatopause. Perspect Brain Aging Res 1: 5-9, 1996

39. Lieberman SA and Hoffman AR. Growth hormone deficiency in adults: characteristics and response to GH replacement. J Pediatr 128: S58-S60, 1996.

40. Hoffman AR and Vu TH. Genomic imprinting. Scientific American: Science and Medicine 3 (1): 52-61, 1996.

41. Lieberman SA and Hoffman AR. The somatopause: should growth hormone deficiency in older people be treated? Clin Geriatr Med 13: 671-684, 1997.

42. Hoffman AR, Lieberman SA, Butterfield G, Thompson J, Hintz RL, Ceda GP, and Marcus R. Functional consequences of the somatopause and its treatment. Endocrine 7: 73-76, 1997.

43. Hoffman AR, Lieberman SA, Marcus R, and Ceda GP. Somatopausa: sei domande in attesta di riposta (Somatopause: six unanswered questions). Aggiornamento medico (Suppl. 10: Invecchiamento e ormoni: prime giornate italiane di endocrinologica geriatrica; a cura di G. Valenti), pp. 2-5, 1997.

44. Marcus R and Hoffman AR. Growth hormone as therapy for older men and women. Annu Rev Pharmacol Toxicol 38: 45-61, 1998.

45. Ceda GP, Valenti G, and Hoffman AR. Estrogen replacement therapy and the response to human growth hormone. In: Veldhuis JD and Giustina A, eds. Sex-steroid interactions with growth hormone. Springer-Verlag, New York, pp. 202-208, 1999.

46. Hoffman AR and Ceda GP. Should we treat the somatopause? J Endocrinol Invest 22 (Suppl. 10): 4-6, 1999.

47. Hu JF and Hoffman AR. Examining histone acetylation at specific genomic regions. In A. Ward (ed).*Methods in Molecular Biology, vol 181:* Genomic Imprinting: Methods and Protocols. Humana Press, Inc., Totowa, NJ. pp. 285-296, 2001.

48. Hoffman AR, Vu TH, and Hu JF. Mechanisms of genomic imprinting. Growth Horm IGF Res

(Suppl A). S18-S19, 2000.

49. Vu TH and Hoffman AR. Comparative genomics sheds light on mechanisms of genomic imprinting. Genome Res 10: 1660-1663, 2000.

50. Hoffman AR. Should we treat the andropause? (editorial) Am J Med 111: 322-323, 2001.

51. Ceda GP, Dall'Aglio E, Salimbeni I, Rocci A, Corradi F, Mazzoni S, Greco F, Ridolo E, Ceresini G, Banchini A, Valenti G and Hoffman AR. Growth hormone (GH) and insulin-like growth factor-1 (IGF-1) in the elderly: clinical trial results. Arch Gerontol Geriatr Suppl. 8: 81-92, 2002.

52. Ceda GP, Dall'Aglio E, Salimbeni I, Rocci A, Mazzoni S, Corradi F, Cattadori E, Visioli S, Banchini A, Ceresini G, Valenti G, and Hoffman AR. Pituitary function in chronic heart failure in the elderly. J Endocrinol Invest 25 (10 Suppl): 24-28, 2002.

53. Hoffman AR and Ceda GP. IGFs and aging: Is there a rationale for hormone replacement therapy? Growth Horm IGF Res 14: 296-300, 2004.

54. Haas RM and Hoffman AR. Treatment of diabetic ketoacidosis: should mode of insulin administration dictate use of intensive care facilities? (editorial). Am J Med 117: 357-358, 2004.

55. Hoffman AR. Treatment of the adult GH deficiency syndrome: directions for future research. Growth Horm IGF Res (in press).

III. BOOKS

Fishman MC, Hoffman AR, Klausner RD, Rockson SG and Thaler MS. Medicine. JB Lippincott Co, Philadelphia, 1981.

Fishman MC, Hoffman AR, Klausner RD, and Thaler MS. ibid. Lippincott Williams & Wilkins
2nd edition, 1985.
3rd edition, 1991.
4th edition, 1996
5th edition, 2004

IV. ELECTRONIC MEDIA

Hoffman AR and Kraemer FB, (Associate editors). Endocrinology/Metabolism/Bone Section. PocketMedicine/Internal Medicine. Bruce F. Scharschmidt, M.D. (editor). Philadelphia; PocketMedicine.com, Inc., 2002.

Hoffman AR. Acromegaly
Hoffman AR. Diabetes insipidus
Hoffman AR. Hypopituitarism
Hoffman AR. Pituitary Tumors
Hoffman AR. Prolactinoma